Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Financing Update

4 Aug 2020 07:00

RNS Number : 0505V
Melrose Industries PLC
04 August 2020
 

MELROSE INDUSTRIES PLC

 

4 August 2020

 

 

FINANCING UPDATE

 

Melrose Industries PLC ("Melrose" or the "Group") today issues an update on financing.

 

Following the trading updates on 30 March 2020 and 22 July 2020, Melrose has now agreed amended arrangements with its banking syndicate including improved financial covenants to 31 December 2022. Beyond that date the Group reverts to the original covenants for the balance of the facilities' term. These amendments cover all the Group's primary borrowing arrangements that contain financial covenants.

 

The Group's committed c.£3.2 billion revolving credit facility is repayable in January 2023 and the Group's committed term loan of c.£0.9 billion can be extended to April 2024 at Melrose's option. In addition to these committed banking lines the Group has two bonds: a £450 million bond maturing in September 2022 and a £300 million bond maturing in May 2032, neither of which contain financial covenants.

 

Melrose is grateful for the continued support of its lending banks which means that it has the flexibility it needs to continue to focus on cash generation and adapting the Group to current market conditions. The new financial covenants have been designed to give Melrose considerable headroom and flexibility.

 

There is a modest cash cost to secure this amendment but there is no change to previously agreed interest rate calculations. Melrose has passed its covenant tests for 30 June 2020 and would not in fact have needed the net debt: EBITDA waiver granted previously.

 

The improved financial covenants are shown in the table below:

 

Financial

Covenant

31 December 2020

30 June 2021

31 December 2021

30 June 2022

31 December 2022

Net debt :EBITDA

Waiver*

Waiver

5.25x**

4.75x**

4.0x**

EBITDA :Net finance charges

2.5x

3.0x

3.0x

3.25x

4.0x

*Announced on 30 March 2020

**Subject to downward adjustments upon certain material disposals

 

Following 31 December 2022, the financial covenants revert to 3.5x (for net debt: EDITDA) and remain at 4x (for EBITDA: net finance charges).

 

 

 

Simon Peckham, CEO of Melrose Industries PLC, said:

"We have now put in place new amended arrangements with our banks that last until the end of 2022. We thank our banks again for their continued support which gives us the headroom and flexibility to continue to focus on cash generation and adapt the Group as needed. Melrose also retains over £1 billion of cash liquidity. We are confident that we can position the Group to produce good returns for Shareholders."

- ends

 

Enquiries:

 

 

Montfort Communications:

Nick Miles

+44 (0) 20 3514 0897

+44 (0) 7973 130 669

miles@montfort.london

Charlotte McMullen

+44 (0) 20 3514 0897

+44 (0) 7921 881 800

mcmullen@montfort.london

Melrose Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEZLBBBVLXBBV
Date   Source Headline
19th Jun 20237:00 amRNSHolding(s) in Company
16th Jun 20234:45 pmRNSDirectorate Change
16th Jun 20231:30 pmRNSHolding(s) in Company
14th Jun 20236:19 pmRNSDirector/PDMR Shareholding
13th Jun 20234:50 pmRNSHolding(s) in Company
9th Jun 202310:00 amRNSHolding(s) in Company
8th Jun 20231:15 pmRNSResult of AGM
2nd Jun 202310:30 amRNSHolding(s) in Company
18th May 20235:15 pmRNSDirector/PDMR Shareholding
18th May 20234:02 pmRNSDirector/PDMR Shareholding
17th May 20231:00 pmRNSCapital Markets Event & New 2025 Guidance
15th May 20237:00 amRNSHolding(s) in Company
11th May 20235:15 pmRNSHolding(s) in Company
10th May 20237:00 amRNSTrading Update & New Guidance
5th May 20237:00 amRNSHolding(s) in Company
4th May 20237:00 amRNSHolding(s) in Company
27th Apr 202311:05 amRNSHolding(s) in Company
25th Apr 20234:35 pmRNSAnnual Report and Notice of Annual General Meeting
21st Apr 20234:00 pmRNSPost-Offer Undertakings Announcement
20th Apr 202312:20 pmRNSHolding(s) in Company
20th Apr 202311:55 amRNSDirector/PDMR Shareholding
20th Apr 20238:14 amRNSCompletion of the demerger of Dowlais
18th Apr 202311:30 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSDirector Declaration
13th Apr 20235:30 pmRNSMelrose Industries
3rd Apr 20237:00 amRNSHolding(s) in Company
31st Mar 20234:00 pmRNSConfirmation of Post-Offer Undertakings
30th Mar 202311:45 amRNSResults of General Meeting
17th Mar 20235:15 pmRNSDirector Declaration
16th Mar 20232:00 pmRNSSecond Interim Dividend - Payment Date
6th Mar 20234:15 pmRNSHolding(s) in Company
3rd Mar 20234:10 pmRNSPublication of a Prospectus
3rd Mar 20234:00 pmRNSCirc re. Demerger Proposal
2nd Mar 20237:00 amRNSFinal Results
17th Feb 20235:00 pmRNSDirector Declaration
31st Jan 20239:45 amRNSHolding(s) in Company
20th Jan 202312:30 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSTrading Update & Capital Markets Event
9th Jan 20237:00 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSCapital Markets Event
16th Nov 20223:00 pmRNSDirector/PDMR Shareholding
15th Nov 20227:00 amRNSTrading Statement
4th Nov 20225:30 pmRNSDirector Declaration
31st Oct 20227:00 amRNSHolding(s) in Company
27th Oct 20225:37 pmRNSHolding(s) in Company
26th Oct 20225:00 pmRNSDirector/PDMR Shareholding
21st Oct 20229:45 amRNSHolding(s) in Company
17th Oct 20223:00 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSHolding(s) in Company
29th Sep 20224:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.